| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1259 | 2018 |
| Global rise in human infectious disease outbreaks KF Smith, M Goldberg, S Rosenthal, L Carlson, J Chen, C Chen, ... Journal of the Royal Society Interface 11 (101), 20140950, 2014 | 720 | 2014 |
| Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient … SHI Ou, J Cui, AB Schrock, ME Goldberg, VW Zhu, L Albacker, ... Lung cancer 108, 228-231, 2017 | 154 | 2017 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 141 | 2021 |
| Genomic correlates of disease progression and treatment response in prospectively characterized gliomas P Jonsson, AL Lin, RJ Young, NM DiStefano, DM Hyman, BT Li, ... Clinical Cancer Research 25 (18), 5537-5547, 2019 | 124 | 2019 |
| High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis RJ Hartmaier, LA Albacker, J Chmielecki, M Bailey, J He, ME Goldberg, ... Cancer research 77 (9), 2464-2475, 2017 | 111 | 2017 |
| Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer RJ Hartmaier, SE Trabucco, N Priedigkeit, JH Chung, CA Parachoniak, ... Annals of oncology 29 (4), 872-880, 2018 | 102 | 2018 |
| Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer JH Chung, D Pavlick, R Hartmaier, AB Schrock, L Young, B Forcier, P Ye, ... Annals of Oncology 28 (11), 2866-2873, 2017 | 79 | 2017 |
| Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies RJ Hartmaier, J Charo, D Fabrizio, ME Goldberg, LA Albacker, W Pao, ... Genome Medicine 9, 1-9, 2017 | 64 | 2017 |
| The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors J Rinaldi, ES Sokol, RJ Hartmaier, SE Trabucco, GM Frampton, ... PLoS One 15 (5), e0231999, 2020 | 40 | 2020 |
| Increased mutation and gene conversion within human segmental duplications MR Vollger, PC Dishuck, WT Harvey, WS DeWitt, X Guitart, ME Goldberg, ... Nature 617 (7960), 325-334, 2023 | 32 | 2023 |
| Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability CC Bieg-Bourne, SZ Millis, DE Piccioni, PT Fanta, ME Goldberg, ... Cancer research 77 (22), 6313-6320, 2017 | 28 | 2017 |
| STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018; 8 (7): 822–835. doi: 10.1158/2159-8290 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... CD-18-0099, 0 | 27 | |
| Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC ME Goldberg, M Montesion, L Young, J Suh, J Greenbowe, M Kennedy, ... PLoS One 13 (11), e0208097, 2018 | 24 | 2018 |
| STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018; 8 (7): 822–35 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... External Resources Crossref (DOI), 0 | 23 | |
| STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.(2018) 8: 822–35. doi: 10.1158/2159-8290 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... CD-18-0099, 0 | 21 | |
| Mutational signatures of replication timing and epigenetic modification persist through the global divergence of mutation spectra across the great ape phylogeny ME Goldberg, K Harris Genome Biology and Evolution 14 (1), evab104, 2022 | 20 | 2022 |
| Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: clinical and ccfDNA studies E Janowski, O Timofeeva, S Chasovskikh, M Goldberg, A Kim, F Banovac, ... Oncology Reports 37 (1), 57-65, 2017 | 19 | 2017 |
| STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8: 822–835 F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... | 16 | 2018 |
| Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database G Singal, PG Miller, V Agarwala, G Li, A Gossai, LA Albacker, ... Annals of Oncology 28, v404-v405, 2017 | 13 | 2017 |
